Table 1 Mean age, gender, race, and myasthenia drug distribution in the two groups
From: Impact of COVID-19 infection among myasthenia gravis patients- a Cerner Real-World DataTM study
COVID Patients with myasthenia (n = 27) | Non-COVID Patients with myasthenia (n = 64) | |||
|---|---|---|---|---|
Mean age (±SD) | 64.33 ± 18.42 (n = 27) | 63.23 ± 18.60 (n = 64) | ||
Mean age (±SD) for patients with exacerbation | 51.5 ± 14.93 (n = 4) | 64.13 ± 17.95 (n = 23) | ||
Female | 13 | 48.15% | 36 | 56.25% |
Male | 13 | 48.15% | 27 | 42.19% |
Unknown | 1 | 3.70% | 1 | 1.56% |
Caucasian | 16 | 59.26% | 46 | 71.88% |
African American | 4 | 14.81% | 8 | 12.50% |
Another racial group | 7 | 25.93% | 10 | 15.62% |
Immune globulin intravenous | 7 | 25.93% | 13 | 20.31% |
Methylprednisolone | 9 | 33.33% | 21 | 32.81% |
Prednisone | 18 | 66.67% | 37 | 57.81% |
Mycophenolate Mofetil | 6 | 22.22% | 3 | 4.69% |
Pyridostigmine | 16 | 59.26% | 33 | 51.56% |